Depot medroxyprogesterone acetate use in inner-city, minority adolescents. Continuation rates and characteristics of long-term users

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objective: To identify continuation rates of depot medroxyprogesterone acetate (Depo-Provera) and characteristics of long-term users in a population of inner-city, minority adolescents with high pregnancy rates. Design: Retrospective medical record review. Setting: An inner-city adolescent clinic and an adolescent pregnancy program. Methods: A review of the medical records of 250 females aged 13 to 20 years (mean ± SD, 16.8 ± 1.1 years), 62.9% Hispanic and 34.2% African American, receiving a first depot medroxyprogesterone acetate injection for contraception between August 1993 and June 1996 was conducted using a standardized form. The mean ± SD age at menarche of the subjects was 11.6 ± 1.4 years, and the mean ± SD age at first intercourse was 14.1 ± 1.3 years; the mean number of lifetime sex partners was 2.4. Of the subjects, 73.6% had used condoms, 32.0% used oral contraceptives, and none used implants. Of the 201 subjects for whom there were data in the medical records regarding prior fertility, 172 (85.6%) had been pregnant, and 145 (72.1%) had a child. Life table analysis was used to measure depot medroxyprogesterone acetate continuation rates and to compare subgroups of adolescents. Results: Depot medroxyprogesterone acetate continuation rates were found to be 70.3% at 6 months, 48.3% at 9 months, 31.5% at 12 months, and 12.8% at 24 months. The most common reason for depot medroxyprogesterone acetate discontinuation was missed appointments (41.7%). Subjects were followed up for a mean ± SD of 1.3 ± 0.7 years after discontinuation of depot medroxyprogesterone acetate use; 46.7% became pregnant. Among those 156 adolescents who discontinued depot medroxyprogesterone acetate use, -0.0% restarted the method at some later time. Continuation of depot medroxyprogesterone acetate use was more likely- if age at first intercourse was younger than 13 years (P = .04). Continuation rates were not related to age, ethnicity, age at menarche, number of sex partners, use of other contraceptives, prior pregnancy, or having a child. Conclusions: In this study, just less than one third of the adolescents continued depot medroxyprogesterone acetate use for 1 year or longer. This suggests that depot medroxyprogesterone acetate does not function as a long- term method for most inner-city adolescents. The only characteristic that was associated with successful continuation of depot medroxyprogesterone acetate use was young age at first intercourse, implying that experience may be the main determinant of continuation.

Original languageEnglish (US)
Pages (from-to)1068-1072
Number of pages5
JournalArchives of Pediatrics and Adolescent Medicine
Volume153
Issue number10
StatePublished - 1999

Fingerprint

Medroxyprogesterone Acetate
Coitus
Medical Records
Menarche
Pregnancy in Adolescence
Life Tables
Condoms
Pregnancy Rate
Oral Contraceptives
Contraceptive Agents
Contraception
Hispanic Americans
African Americans
Fertility
Appointments and Schedules

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

@article{21108824b53c49718ed0cabb8b182564,
title = "Depot medroxyprogesterone acetate use in inner-city, minority adolescents. Continuation rates and characteristics of long-term users",
abstract = "Objective: To identify continuation rates of depot medroxyprogesterone acetate (Depo-Provera) and characteristics of long-term users in a population of inner-city, minority adolescents with high pregnancy rates. Design: Retrospective medical record review. Setting: An inner-city adolescent clinic and an adolescent pregnancy program. Methods: A review of the medical records of 250 females aged 13 to 20 years (mean ± SD, 16.8 ± 1.1 years), 62.9{\%} Hispanic and 34.2{\%} African American, receiving a first depot medroxyprogesterone acetate injection for contraception between August 1993 and June 1996 was conducted using a standardized form. The mean ± SD age at menarche of the subjects was 11.6 ± 1.4 years, and the mean ± SD age at first intercourse was 14.1 ± 1.3 years; the mean number of lifetime sex partners was 2.4. Of the subjects, 73.6{\%} had used condoms, 32.0{\%} used oral contraceptives, and none used implants. Of the 201 subjects for whom there were data in the medical records regarding prior fertility, 172 (85.6{\%}) had been pregnant, and 145 (72.1{\%}) had a child. Life table analysis was used to measure depot medroxyprogesterone acetate continuation rates and to compare subgroups of adolescents. Results: Depot medroxyprogesterone acetate continuation rates were found to be 70.3{\%} at 6 months, 48.3{\%} at 9 months, 31.5{\%} at 12 months, and 12.8{\%} at 24 months. The most common reason for depot medroxyprogesterone acetate discontinuation was missed appointments (41.7{\%}). Subjects were followed up for a mean ± SD of 1.3 ± 0.7 years after discontinuation of depot medroxyprogesterone acetate use; 46.7{\%} became pregnant. Among those 156 adolescents who discontinued depot medroxyprogesterone acetate use, -0.0{\%} restarted the method at some later time. Continuation of depot medroxyprogesterone acetate use was more likely- if age at first intercourse was younger than 13 years (P = .04). Continuation rates were not related to age, ethnicity, age at menarche, number of sex partners, use of other contraceptives, prior pregnancy, or having a child. Conclusions: In this study, just less than one third of the adolescents continued depot medroxyprogesterone acetate use for 1 year or longer. This suggests that depot medroxyprogesterone acetate does not function as a long- term method for most inner-city adolescents. The only characteristic that was associated with successful continuation of depot medroxyprogesterone acetate use was young age at first intercourse, implying that experience may be the main determinant of continuation.",
author = "Lim, {Sylvia W.} and Jessica Rieder and Coupey, {Susan M.} and Bijur, {Polly E.}",
year = "1999",
language = "English (US)",
volume = "153",
pages = "1068--1072",
journal = "JAMA Pediatrics",
issn = "2168-6203",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Depot medroxyprogesterone acetate use in inner-city, minority adolescents. Continuation rates and characteristics of long-term users

AU - Lim, Sylvia W.

AU - Rieder, Jessica

AU - Coupey, Susan M.

AU - Bijur, Polly E.

PY - 1999

Y1 - 1999

N2 - Objective: To identify continuation rates of depot medroxyprogesterone acetate (Depo-Provera) and characteristics of long-term users in a population of inner-city, minority adolescents with high pregnancy rates. Design: Retrospective medical record review. Setting: An inner-city adolescent clinic and an adolescent pregnancy program. Methods: A review of the medical records of 250 females aged 13 to 20 years (mean ± SD, 16.8 ± 1.1 years), 62.9% Hispanic and 34.2% African American, receiving a first depot medroxyprogesterone acetate injection for contraception between August 1993 and June 1996 was conducted using a standardized form. The mean ± SD age at menarche of the subjects was 11.6 ± 1.4 years, and the mean ± SD age at first intercourse was 14.1 ± 1.3 years; the mean number of lifetime sex partners was 2.4. Of the subjects, 73.6% had used condoms, 32.0% used oral contraceptives, and none used implants. Of the 201 subjects for whom there were data in the medical records regarding prior fertility, 172 (85.6%) had been pregnant, and 145 (72.1%) had a child. Life table analysis was used to measure depot medroxyprogesterone acetate continuation rates and to compare subgroups of adolescents. Results: Depot medroxyprogesterone acetate continuation rates were found to be 70.3% at 6 months, 48.3% at 9 months, 31.5% at 12 months, and 12.8% at 24 months. The most common reason for depot medroxyprogesterone acetate discontinuation was missed appointments (41.7%). Subjects were followed up for a mean ± SD of 1.3 ± 0.7 years after discontinuation of depot medroxyprogesterone acetate use; 46.7% became pregnant. Among those 156 adolescents who discontinued depot medroxyprogesterone acetate use, -0.0% restarted the method at some later time. Continuation of depot medroxyprogesterone acetate use was more likely- if age at first intercourse was younger than 13 years (P = .04). Continuation rates were not related to age, ethnicity, age at menarche, number of sex partners, use of other contraceptives, prior pregnancy, or having a child. Conclusions: In this study, just less than one third of the adolescents continued depot medroxyprogesterone acetate use for 1 year or longer. This suggests that depot medroxyprogesterone acetate does not function as a long- term method for most inner-city adolescents. The only characteristic that was associated with successful continuation of depot medroxyprogesterone acetate use was young age at first intercourse, implying that experience may be the main determinant of continuation.

AB - Objective: To identify continuation rates of depot medroxyprogesterone acetate (Depo-Provera) and characteristics of long-term users in a population of inner-city, minority adolescents with high pregnancy rates. Design: Retrospective medical record review. Setting: An inner-city adolescent clinic and an adolescent pregnancy program. Methods: A review of the medical records of 250 females aged 13 to 20 years (mean ± SD, 16.8 ± 1.1 years), 62.9% Hispanic and 34.2% African American, receiving a first depot medroxyprogesterone acetate injection for contraception between August 1993 and June 1996 was conducted using a standardized form. The mean ± SD age at menarche of the subjects was 11.6 ± 1.4 years, and the mean ± SD age at first intercourse was 14.1 ± 1.3 years; the mean number of lifetime sex partners was 2.4. Of the subjects, 73.6% had used condoms, 32.0% used oral contraceptives, and none used implants. Of the 201 subjects for whom there were data in the medical records regarding prior fertility, 172 (85.6%) had been pregnant, and 145 (72.1%) had a child. Life table analysis was used to measure depot medroxyprogesterone acetate continuation rates and to compare subgroups of adolescents. Results: Depot medroxyprogesterone acetate continuation rates were found to be 70.3% at 6 months, 48.3% at 9 months, 31.5% at 12 months, and 12.8% at 24 months. The most common reason for depot medroxyprogesterone acetate discontinuation was missed appointments (41.7%). Subjects were followed up for a mean ± SD of 1.3 ± 0.7 years after discontinuation of depot medroxyprogesterone acetate use; 46.7% became pregnant. Among those 156 adolescents who discontinued depot medroxyprogesterone acetate use, -0.0% restarted the method at some later time. Continuation of depot medroxyprogesterone acetate use was more likely- if age at first intercourse was younger than 13 years (P = .04). Continuation rates were not related to age, ethnicity, age at menarche, number of sex partners, use of other contraceptives, prior pregnancy, or having a child. Conclusions: In this study, just less than one third of the adolescents continued depot medroxyprogesterone acetate use for 1 year or longer. This suggests that depot medroxyprogesterone acetate does not function as a long- term method for most inner-city adolescents. The only characteristic that was associated with successful continuation of depot medroxyprogesterone acetate use was young age at first intercourse, implying that experience may be the main determinant of continuation.

UR - http://www.scopus.com/inward/record.url?scp=0032825516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032825516&partnerID=8YFLogxK

M3 - Article

C2 - 10520615

AN - SCOPUS:0032825516

VL - 153

SP - 1068

EP - 1072

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 2168-6203

IS - 10

ER -